Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Albuminuria in Type 2 Diabetes
NCT02545738Phase 4Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liraglutide in type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD) (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Change in albuminuria at 24 weeks. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT02545738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545738.